Brought to you by 
Aquinox raises $25mm through Series B round
14 Sep 2020
Executive Summary
Aquinox Pharmaceuticals Inc. (therapies for cancer and inflammatory, blood, and immune diseases) raised $25mm through its Series B round. New investor Pfizer Venture Investments was joined by returning backers Johnson & Johnson Development Corp., Baker Brothers Investments, and BC Advantage Funds. Aquinox will use the proceeds to advance its lead candidate AQX1125 into Phase I and II trials for blood and immune conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aquinox raises $25mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice